Literature DB >> 20212014

N-desmethyl-loperamide is selective for P-glycoprotein among three ATP-binding cassette transporters at the blood-brain barrier.

Pavitra Kannan1, Kyle R Brimacombe, Sami S Zoghbi, Jeih-San Liow, Cheryl Morse, Andrew K Taku, Victor W Pike, Christer Halldin, Robert B Innis, Michael M Gottesman, Matthew D Hall.   

Abstract

[(11)C]N-desmethyl-Loperamide ([(11)C]dLop) is used in positron emission tomography (PET) to measure the in vivo activity of efflux transporters that block the passage of drugs across the blood-brain barrier. The three most prevalent ATP-binding cassette efflux transporters at the blood-brain barrier are P-glycoprotein (P-gp), multidrug resistance protein 1 (Mrp1), and breast cancer resistance protein (BCRP). We sought to measure the selectivity of dLop among these three transporters. The selectivity of dLop at low concentrations (< or =1 nM) was measured both as the accumulation of [(3)H]dLop in human cells that overexpress each transporter and as the uptake of [(11)C]dLop in brains of mice that lack genes encoding P-gp, Mrp1, or BCRP. The selectivity of dLop at high concentrations (> or =20 microM) was measured as the inhibition of uptake of a fluorescent substrate and the change in cytotoxicity of drugs effluxed at each transporter. Accumulation of [(3)H]dLop was lowest in cells overexpressing P-gp, and the uptake of [(11)C]dLop was highest in brains of mice lacking P-gp. At high concentrations, dLop selectively inhibited P-gp function and also decreased the resistance of only the P-gp-expressing cells to cytotoxic agents. dLop is selective for P-gp among these three transporters, but its activity is dependent on concentration. At low concentrations (< or =1 nM), dLop acts only as a substrate; at high concentrations (> or =20 microM), it acts as both a substrate and an inhibitor (i.e., a competitive substrate). Because low concentrations of radiotracer are used for PET imaging, [(11)C]dLop acts selectively and only as a substrate for P-gp.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20212014      PMCID: PMC2879961          DOI: 10.1124/dmd.109.031161

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  30 in total

Review 1.  Multidrug resistance in cancer: role of ATP-dependent transporters.

Authors:  Michael M Gottesman; Tito Fojo; Susan E Bates
Journal:  Nat Rev Cancer       Date:  2002-01       Impact factor: 60.716

Review 2.  Drug transport at the blood-brain barrier and the choroid plexus.

Authors:  Candace L Graff; Gary M Pollack
Journal:  Curr Drug Metab       Date:  2004-02       Impact factor: 3.731

3.  P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide.

Authors:  William C Kreisl; Jeih-San Liow; Nobuyo Kimura; Nicholas Seneca; Sami S Zoghbi; Cheryl L Morse; Peter Herscovitch; Victor W Pike; Robert B Innis
Journal:  J Nucl Med       Date:  2010-03-17       Impact factor: 10.057

4.  Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins.

Authors:  D W Shen; C Cardarelli; J Hwang; M Cornwell; N Richert; S Ishii; I Pastan; M M Gottesman
Journal:  J Biol Chem       Date:  1986-06-15       Impact factor: 5.157

Review 5.  Mechanisms of cancer drug resistance.

Authors:  Michael M Gottesman
Journal:  Annu Rev Med       Date:  2002       Impact factor: 13.739

6.  Pheophorbide a is a specific probe for ABCG2 function and inhibition.

Authors:  Robert W Robey; Kenneth Steadman; Orsolya Polgar; Kuniaki Morisaki; Margaret Blayney; Prakash Mistry; Susan E Bates
Journal:  Cancer Res       Date:  2004-02-15       Impact factor: 12.701

7.  Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport.

Authors:  Stina Syvänen; Orjan Lindhe; Mikael Palner; Birgitte R Kornum; Obaidur Rahman; Bengt Långström; Gitte M Knudsen; Margareta Hammarlund-Udenaes
Journal:  Drug Metab Dispos       Date:  2008-12-01       Impact factor: 3.922

8.  Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex.

Authors:  D Piwnica-Worms; M L Chiu; M Budding; J F Kronauge; R A Kramer; J M Croop
Journal:  Cancer Res       Date:  1993-03-01       Impact factor: 12.701

9.  A dual-fluorescence high-throughput cell line system for probing multidrug resistance.

Authors:  Kyle R Brimacombe; Matthew D Hall; Douglas S Auld; James Inglese; Christopher P Austin; Michael M Gottesman; King-Leung Fung
Journal:  Assay Drug Dev Technol       Date:  2009-06       Impact factor: 1.738

10.  Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.

Authors:  E Schneider; J K Horton; C H Yang; M Nakagawa; K H Cowan
Journal:  Cancer Res       Date:  1994-01-01       Impact factor: 12.701

View more
  18 in total

1.  The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2).

Authors:  Pavitra Kannan; Sanjay Telu; Suneet Shukla; Suresh V Ambudkar; Victor W Pike; Christer Halldin; Michael M Gottesman; Robert B Innis; Matthew D Hall
Journal:  ACS Chem Neurosci       Date:  2010-10-21       Impact factor: 4.418

2.  The Inhibitor Ko143 Is Not Specific for ABCG2.

Authors:  Lora D Weidner; Sami S Zoghbi; Shuiyu Lu; Suneet Shukla; Suresh V Ambudkar; Victor W Pike; Jan Mulder; Michael M Gottesman; Robert B Innis; Matthew D Hall
Journal:  J Pharmacol Exp Ther       Date:  2015-07-06       Impact factor: 4.030

3.  Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET.

Authors:  Pavitra Kannan; Kyle R Brimacombe; William C Kreisl; Jeih-San Liow; Sami S Zoghbi; Sanjay Telu; Yi Zhang; Victor W Pike; Christer Halldin; Michael M Gottesman; Robert B Innis; Matthew D Hall
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-24       Impact factor: 11.205

4.  Reduced accumulation of platinum drugs is not observed in drug-resistant ovarian cancer cell lines derived from cisplatin-treated patients.

Authors:  Marina Stukova; Matthew D Hall; Samantha D Tsotsoros; James P Madigan; Nicholas P Farrell; Michael M Gottesman
Journal:  J Inorg Biochem       Date:  2015-05-14       Impact factor: 4.155

Review 5.  PET and SPECT radiotracers to assess function and expression of ABC transporters in vivo.

Authors:  Severin Mairinger; Thomas Erker; Markus Muller; Oliver Langer
Journal:  Curr Drug Metab       Date:  2011-10       Impact factor: 3.731

Review 6.  Advances in PET imaging of P-glycoprotein function at the blood-brain barrier.

Authors:  Stina Syvänen; Jonas Eriksson
Journal:  ACS Chem Neurosci       Date:  2012-12-04       Impact factor: 4.418

7.  Overlapping substrate and inhibitor specificity of human and murine ABCG2.

Authors:  Joshua Bakhsheshian; Matthew D Hall; Robert W Robey; Michelle A Herrmann; Jin-Qiu Chen; Susan E Bates; Michael M Gottesman
Journal:  Drug Metab Dispos       Date:  2013-07-18       Impact factor: 3.922

8.  (18)F-FCWAY, a serotonin 1A receptor radioligand, is a substrate for efflux transport at the human blood-brain barrier.

Authors:  Jeih-San Liow; Sami S Zoghbi; Shuo Hu; Matthew D Hall; Christina S Hines; H Umesha Shetty; Maria D Araneta; Emily M Page; Victor W Pike; William C Kreisl; Peter Herscovitch; Michael M Gottesman; William H Theodore; Robert B Innis
Journal:  Neuroimage       Date:  2016-05-19       Impact factor: 6.556

9.  Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2.

Authors:  Joshua Bakhsheshian; Bih-Rong Wei; Ki-Eun Chang; Suneet Shukla; Suresh V Ambudkar; R Mark Simpson; Michael M Gottesman; Matthew D Hall
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-02       Impact factor: 11.205

10.  Screening compounds with a novel high-throughput ABCB1-mediated efflux assay identifies drugs with known therapeutic targets at risk for multidrug resistance interference.

Authors:  Megan R Ansbro; Suneet Shukla; Suresh V Ambudkar; Stuart H Yuspa; Luowei Li
Journal:  PLoS One       Date:  2013-04-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.